Navigation Links
Wilson Therapeutics Announces Successful Filing of U.S. IND to Advance WTX101 Development Program for Wilson Disease
Date:1/13/2014

STOCKHOLM, Jan. 13, 2014 /PRNewswire/ -- Wilson Therapeutics, a privately-held biopharmaceutical company, today announced that it has successfully filed an Investigational New Drug (IND) application with U.S. Food and Drug Administration for the development of WTX101 (bis-choline tetrathiomolybdate), a novel de-coppering agent under evaluation as a treatment for Wilson Disease. The recent acceptance of the U.S. IND is a key initial step in the company's plan to advance WTX101 into pivotal clinical trials as a treatment for Wilson Disease, a rare genetic disorder that prevents the body from regulating copper and can lead to serious liver and brain damages.

"This IND enables us to proceed with a Phase 1 study that will provide additional pharmacokinetic and bioavailability data to support the overall development of WTX101 as it moves towards late stage, pivotal trials," said David Clark, M.D., chief medical officer of Wilson Therapeutics. "We expect to conduct this study quickly as we advance the WTX101 program forward this year."

WTX101 is the proprietary bis-choline formulation of tetrathiomolybdate (TTM), which has been evaluated in clinical studies in over 500 patients in various indications. TTM has been shown to rapidly lower copper levels. Previous data also suggest that TTM may stabilize neurological function and reduce the risk of neurological deterioration after initiation of treatment in Wilson Disease patients with neurological disease. WTX101 has also been tested in oncologic clinical trials and was shown to be safe and tolerable while efficiently lowering copper levels with once-daily dosing. WTX101 has received orphan drug designation in both the United States and the European Union.

"There remains a serious unmet need in the treatment of Wilson Disease patients, particularly those who present wit
'/>"/>

SOURCE Wilson Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Wilson Sonsini Goodrich & Rosati Elects Four New Partners
2. Charlie Wilson Teams Up With Janssen Biotech to Launch Making Awareness a Priority (M.A.P.)
3. TrialNetworks Customer Steve Sweeney of Arteaus Therapeutics Encourages Clinical Trial Sponsors to Treat Investigative Sites Like Customers by Using Innovative Technology
4. Halozyme Therapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference
5. Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors
6. Spark Therapeutics Expands Leadership Team to Support Development and Commercialization of its Late-Stage Gene Therapy Pipeline
7. Adheron Therapeutics Announces Favorable Phase 1 Clinical Trial Results
8. Todd Rider Joins Draper to Continue Antiviral Therapeutics Development
9. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
10. Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
11. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 “Preparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ...
(Date:12/24/2014)... Earlier this year in a June 24 international conference presentation, ... Technology Center, LLC ( ASCTC ) focused attention on an ... stem cells. His title “Asymmetric Self-Renewal by Distributed Stem ... the essence of his message to congress participants. He ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Veracyte, Inc ., a molecular diagnostics company pioneering the ... of Mark Spring as chief financial officer. ... the Veracyte team," said Bonnie Anderson, Veracyte,s cofounder and ... and senior finance leader in both public and private ...
... Calif., Jan. 26, 2012 Cepheid (Nasdaq: CPHD ... of $80.1 million.  Net loss was $1.6 million, or $(0.03) ... net income of $1.3 million, or $0.02 per diluted share, ... quarter net loss reflected a one-time, non-cash charge to cost ...
... Lend Lease is pleased to announce the appointment of ... Sciences group in the Atlantic Region.  Tom rejoined Lend ... of the Raleigh, NC office, working closely with the regional ... Atlantic offices. He will report directly to Steve Eberling, ...
Cached Biology Technology:Veracyte Appoints Mark Spring as Chief Financial Officer 2Veracyte Appoints Mark Spring as Chief Financial Officer 3Cepheid Reports Fourth Quarter and Full Year 2011 Results 2Cepheid Reports Fourth Quarter and Full Year 2011 Results 3Cepheid Reports Fourth Quarter and Full Year 2011 Results 4Cepheid Reports Fourth Quarter and Full Year 2011 Results 5Cepheid Reports Fourth Quarter and Full Year 2011 Results 6Cepheid Reports Fourth Quarter and Full Year 2011 Results 7Cepheid Reports Fourth Quarter and Full Year 2011 Results 8Cepheid Reports Fourth Quarter and Full Year 2011 Results 9Cepheid Reports Fourth Quarter and Full Year 2011 Results 10Cepheid Reports Fourth Quarter and Full Year 2011 Results 11Lend Lease Announces the Appointment of Tom Chapman as Director Operations for the Life Sciences Group in the Atlantic Region 2
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in the ... One major trend emerging in this market is ... is important to upgrade biometric solutions to the latest ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... producing proteins that moonlight, having different roles at different ... killed. The moonlighting activity of one enzyme from the ... of broad-spectrum antibiotics, according to a paper published in ... "Glutamate racemase, or MurI, is an enzyme ...
... many recent reports documenting the therapeutic efficacy of short ... may actually be describing non-specific therapeutic effects related to ... according to a paper in the September 2008 issue ... , a peer-reviewed journal published by Mary Ann Liebert, ...
... NY, Sept. 2, 2008) People concerned about the ... families and communities will have a unique opportunity to ... about the causes, symptoms and progression of such illnesses ... learn about current and potential treatments. In an ...
Cached Biology News:Energy-saving bacteria resist antibiotics 2Previous claims of siRNA therapeutic effects called into question by report in human gene therapy 2Healthy Minds Across America features 48 public forums on mental health research, Sept. 14 2Healthy Minds Across America features 48 public forums on mental health research, Sept. 14 3
Antibodies were affinity purified using epitopes specific to JLP immobilized on solid support....
... Edited by N.C. Price ... detailed information on protein chemistry ... characterization of proteins. Data on ... Chromatography, crystalization, size determination, amino ...
... B.S. Dunbar (1994) • This ... principles and methods for preparing samples ... such as radiometric and bioluminescence-enhanced detection ... covered are, the detection and characterization ...
See product name for description....
Biology Products: